The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Buprenorphine Treatment of Refractory Depression
Abstract
Opiates were used to treat major depression until the mid-1950s. The advent of opioids with mixed agonist-antagonist or partial agonist activity, with reduced dependence and abuse liabilities, has made possible the reevaluation of opioids for this indication. This is of potential importance for the population of depressed patients who are unresponsive to or intolerant of conventional antidepressant agents. Ten subjects with treatment-refractory, unipolar, nonpsychotic, major depression were treated with the opioid partial agonist buprenorphine in an open-label study. Three subjects were unable to tolerate more than two doses because of side effects including malaise, nausea, and dysphoria. The remaining seven completed 4 to 6 weeks of treatment and as a group showed clinically striking improvement in both subjective and objective measures of depression. Much of this improvement was observed by the end of 1 week of treatment and persisted throughout the trial. Four subjects achieved complete remission of symptoms by the end of the trial (Hamilton Rating Scale for Depression scores < or = 6), two were moderately improved, and one deteriorated. These findings suggest a possible role for buprenorphine in treating refractory depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Buprenorphine has antidepressant effects when used for both opioid use disorder and treatment-resistant depression (279-284)”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [279]
In the citing paper
“Overall, six clinical trials [41,42,43,44,45,46]—of which three were randomized, double-blind and placebo controlled studies [41,44,45]—and one clinical case [47], including a total of 216 subjects with TRD treated with BUP in mono-therapy or together with an opioid antagonist (naloxone or samidorphan) were included.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Bodkin [42] treated 10 TRD subjects with BUP, according to tolerance and clinical benefits, with a maximum daily dosage of 1.8 mg. After four to six weeks, seven patients showed clinically striking improvements in both subjective and objective measures of depression.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Taken together, according to the included studies, BUP has a rapid antidepressant and anti-suicidal action: in fact, this psychoactive compound seems to act in about a week after the first administration [41,42,43,44,46,47,48,52].”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Bodkin and colleagues [42] and Gerra et al. [50] even reported some cases of irritability, anxiety, and dysphoria, which led to drop-out from the study of implicated patients.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Not all the studies included in this review analyzed the occurrence of side effects related to BUP use but, in those who considered their possible emergence [42,43,44,45,46,50,51], specific side-effects were described in the majority of patients.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“On the other hand, there are also studies [42,47,48,50,51] suggesting that this action is prolonged in time up to one to three months.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Opioid analgesics and antagonists
Reisine, T. (1996) · Medical Entomology and Zoology · Cited by 1,205
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.1992.03480200058024 · Cited by 567
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Buprenorphine suppresses heroin use by heroin addicts
Mello, N. K., & Mendelson, J. H. (1980) · Science · doi:10.1126/science.7352279 · Cited by 298
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I. A., Jasinski, D. R., & Johnson, R. E. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20047-7 · Cited by 226
Regionally selective increases in μ opioid receptor density in the brains of suicide victims
Gross‐Isseroff, R., Dillon, K. A., Israeli, M., & Biegon, A. R. (1990) · Brain Research · doi:10.1016/0006-8993(90)91301-v · Cited by 221
(1990) · PubMed · Cited by 199
A controlled trial of buprenorphine treatment for opioid dependence
Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.267.20.2750 · Cited by 199
Research works printed but not linked: 8
- Carlson, 1963, Am J Psychiatry, 112-, 7
- Lehmann, 1971, Curr Ther Res, 13, 42
- Exstein, 1981, Psychopharmacol Bull, 17, 29
- Resnick, 1992, Psychopharmacol Bull, 28, 109
- Banks, 1979, N Z Med J, 89, 255
- Thase, 1992, J Clin Psychiatry, 53, 5
- Bickel, 1988, J Psychopharmacol Exp Ther, 247, 47
- Harrison, 1988, Psychopharmacol Bull, 24, 9
Cited by
Sorted by citations
Items 201–300 of 352
Panksepp, J. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_458 · Cited by 22
Rosa, S. G., Pesarico, A. P., Tagliapietra, C. F., da Luz, S. C. A., & Nogueira, C. W. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117724353 · Cited by 20
Thase, M. E., Stanford, A. D., Memisoglu, A., Martin, W. F., Claxton, A., Bodkin, J. A., Trivedi, M. H., D, M. F. M., Yu, M., & Pathak, S. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0451-3 · Cited by 20
Self-citationDinoff, A., Lynch, S. T., Sekhri, N. K., & Klepacz, L. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.089 · Cited by 20
Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine
Cameron, C. M., Nieto, S. J., Bosler, L., Wong, M. H., Bishop, I., Mooney, L. J., & Cahill, C. M. (2021) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2021.10009 · Cited by 20
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 20
Development of New Psychopharmacological Agents for Depression and Anxiety
Schatzberg, A. F. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.05.009 · Cited by 19
Buprenorphine: prospective novel therapy for depression and PTSD
Madison, C. A., & Eitan, S. (2020) · Psychological Medicine · doi:10.1017/s0033291720000525 · Cited by 21
Lin, C., Karim, H. T., Peciña, M., Aizenstein, H. J., Lenze, E. J., Blumberger, D. M., Mulsant, B. H., Kharasch, E. D., Reynolds, C. F., & Karp, J. F. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101679 · Cited by 19
Peckham, A., Griffin, M. L., McHugh, R. K., & Weiss, R. D. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108122 · Cited by 19
Varastehmoradi, B., Wegener, G., Sánchez, C., & Smith, K. L. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000559 · Cited by 17
Substance Abuse and Depression
Renner, J. A., Baxter, J., Suzuki, J., & Ciraulo, D. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-435-7_6 · Cited by 17
Multiple Sclerosis and the Endogenous Opioid System
Dworsky-Fried, Z., Chadwick, C. I., Kerr, B. J., & Taylor, A. M. W. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.741503 · Cited by 17
Upadhyay, J., Verrico, C. D., Cay, M., Kodele, S., Yammine, L., Koob, G. F., & Schreiber, R. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00008-0 · Cited by 16
Farmany, A., Shamsara, M., & Mahdavi, H. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.08.007 · Cited by 17
Delta Opioids: Neuroprotective Roles in Preclinical Studies
Husain, S. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0039 · Cited by 16
The Vicissitudes of Preclinical Psychiatric Research: Justified Abandonment By Big Pharma?
Panksepp, J. (2012) · Future Neurology · doi:10.2217/fnl.12.1 · Cited by 16
Old Versus New Medications: How Much Should Be Taught?
Jefferson, J. W. (2005) · Academic Psychiatry · doi:10.1176/appi.ap.29.2.162 · Cited by 16
Minimally invasive detection of buprenorphine using a carbon-coated 3D-printed microneedle array
Kadian, S., Sahoo, S. S., Kumari, P., Shukla, S., & Narayan, R. J. (2024) · Microchimica Acta · doi:10.1007/s00604-024-06754-x · Cited by 16
Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality
Kelty, E. A., Hulse, G. K., Joyce, D. A., & Preen, D. B. (2020) · CNS Drugs · doi:10.1007/s40263-020-00719-3 · Cited by 15
Masoumi, S., & Esmaeili, A. (2020) · Applied Nanoscience · doi:10.1007/s13204-020-01545-1 · Cited by 15
Bastien, G., McAnulty, C., Ledjiar, O., Socias, M. E., Foll, B. L., Lim, R., Hassan, A. N., Brissette, S., Marsan, S., Talbot, A., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221145013 · Cited by 14
Vest, N. A., McPherson, S., Burns, G. L., & Tragesser, S. L. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107940 · Cited by 15
Prenatal Buprenorphine Exposure and Sexually Dimorphic Nonreproductive Behaviors in Rats
Barron, S. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00260-8 · Cited by 14
Burke, N. N., Ferdousi, M. I., Deaver, D. R., Finn, D. P., Roche, M., & Kelly, J. P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.012 · Cited by 13
Dolatshahi, M., Davoudi, S., Paridar, Y., Naserzadeh, R., & Ghorbanzadeh, B. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134578 · Cited by 13
Skadberg, R. M., Moore, T. M., & Elledge, L. C. (2020) · Pain Management · doi:10.2217/pmt-2019-0037 · Cited by 13
Yang, S., Zhang, L., Ge, Y.-J., Zhang, J., Hu, J., Shen, C., Lü, A., Hou, T., & Cao, D. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00720-0 · Cited by 13
Effect of Tramadol/Acetaminophen on Motivation in Patients with Chronic Low Back Pain
Tetsunaga, T., Tetsunaga, T., Tanaka, M., Nishida, K., Takei, Y., & Ozaki, T. (2016) · Pain Research and Management · doi:10.1155/2016/7458534 · Cited by 13
7β-Methyl substituent is a structural locus associated with activity cliff for nepenthone analogues
Sun, H., Wang, Y., Yuan, C., Kong, L., Xu, X., Wang, Y.-J., Wu, H.-H., Lin, C., Qian, Y., Huang, H., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.07.020 · Cited by 13
Opioidergic Agents as Antidepressants: Rationale and Promise
Saxena, P. P., & Bodkin, J. A. (2018) · CNS Drugs · doi:10.1007/s40263-018-0584-7 · Cited by 13
Self-citationFatal Body Dysmorphic Disorder by Proxy
Atiullah, N., & Phillips, K. A. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0312a · Cited by 13
Therapeutic Armamentarium for Treating Depression
Howland, R. H. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2176 · Cited by 14
Lee, H. H., Blumberger, D. M., Lenze, E. J., Anderson, S. J., Barch, D. M., Black, K. J., Cristancho, P., Daskalakis, Z. J., Eisenstein, S. A., Huang, Y., et al. (2022) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.09.003 · Cited by 15
Pathak, S., Vince, B. D., Kelsh, D., Shram, M. J., Setnik, B., Lu, H. L., Nangia, N., Stanford, A. D., & Ehrich, E. W. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1280 · Cited by 12
Roques, B. P. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_17 · Cited by 11
Normansell, L., & Panksepp, J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.06.004 · Cited by 11
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression
Nemeroff, C. B. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21121204 · Cited by 11
Robinson, S. A., Hill‐Smith, T. E., & Lucki, I. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100182 · Cited by 11
Opioid Mechanisms and the Treatment of Depression
Jelen, L. A., Young, A. H., & Mehta, M. A. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_448 · Cited by 10
Clark, S. D. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_396 · Cited by 10
Kosten, T. R. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010078 · Cited by 10
Opioids in Psychiatric Disorders: Back to the Future?
Schatzberg, A. F. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15101354 · Cited by 9
Solms, M. (2012) · PsycEXTRA Dataset · doi:10.1037/e579192013-150 · Cited by 9
Opioid Analgesics and Depressive Symptoms in Burn Patients: What Is the Real Relationship?
Hong, N., Jung, M., Kim, J. W., Chun, W., Choi, I., Kang, T.-C., Kee, B., & Lee, B. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.3.295 · Cited by 6
Sokhadze, E. M., Trudeau, D. L., & Cannon, R. L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396988-0.00011-8 · Cited by 8
Javelot, H. (2015) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2015.09.001 · Cited by 8
Psychotropic Drugs in Terminally Ill Patients: A Review of the Clinical and Research Literature
Templer, D. I., Arikawa, H., & Gariety, P. C. (2004) · OMEGA - Journal of Death and Dying · doi:10.2190/9v5j-fg82-qrrn-uf87 · Cited by 8
Saporito, M. S., Lipinski, C. A., & Reaume, A. G. (2012) · doi:10.1002/9781118274408.ch9 · Cited by 8
Commentary on “Integrating the Psychoanalytic and Neurobiological Views of Panic Disorder”
Panksepp, J. (2005) · Neuropsychoanalysis · doi:10.1080/15294145.2005.10773487 · Cited by 8
Maremmani, A. G. I., Rugani, F., Bacciardi, S., Rovai, L., Massimetti, E., Gazzarrini, D., Dell’Osso, L., & Maremmani, I. (2014) · Journal of Addictive Diseases · doi:10.1080/10550887.2014.975608 · Cited by 7
The use of buprenorphine in the treatment of drug-resistant depression – an overview of the studies
Stefanowski, B., Antosik-Wójcińska, A. Z., & Święcicki, Ł. (2020) · Psychiatria Polska · doi:10.12740/pp/102658 · Cited by 8
Malcolm‐Smith, S., Thomas, K. G. F., Ipser, J., Stein, D. J., van Honk, J., & Solms, M. (2013) · Neuropsychoanalysis · doi:10.1080/15294145.2013.10799826 · Cited by 7
Marek, G. J. (2000) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2000.tb00148.x · Cited by 7
Matussek, N. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003808 · Cited by 7
Effect of imipramine on enkephalin-degrading peptidases
Gandarías, J. M., Irazusta, J., Varona, A., Gil, J., Fernández, D., & Casis, L. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00035-8 · Cited by 7
Ahmadi, J., & Abtahi, S. (2017) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.59999 · Cited by 6
Kelty, E. A., & Hulse, G. K. (2017) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-017-9856-6 · Cited by 6
OPIOIDS IN PAIN SYNDROME MANAGEMENT (PART 2)
Arbuck, D. M., Gr, A., & Alekseeva, G. S. (2017) · Messenger of Anesthesiology and Resuscitation · doi:10.21292/2078-5658-2017-14-4-61-71 · Cited by 6
Iovine, P. A., Drachman, D., & Kirane, H. (2020) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2020.1838859 · Cited by 6
theraTRACE®: a mechanism unbiased in vivo platform for phenotypic screening and drug repositioning
Saporito, M. S., & Reaume, A. G. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.06.002 · Cited by 6
Words of Caution on Using Fixed 50% Concentrations of Nitrous Oxide in Psychiatry
Gillman, M. A. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001067 · Cited by 6
Eficacia y manejo clínico de la buprenorfina
Roncero, C., Sáez‐Francàs, N., Cervelló, X. C., & Casas, M. (2008) · Trastornos Adictivos · doi:10.1016/s1575-0973(08)74549-5 · Cited by 6
Maremmani, A. G. I., Bacciardi, S., Rovai, L., Rugani, F., Dell’Osso, L., & Maremmani, I. (2012) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0b013e31824c5d1b · Cited by 6
Another marker for different types of depression
LICHTIGFELD, F. J., & Gillman, M. A. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003286 · Cited by 6
Opiate drugs: ‘guilt by association’
Evans, C. J., Monteillet-Agius, G., Saliminejad, N., & Zaki, P. A. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000739 · Cited by 6
Marek, G. J., & Ramos, B. P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00089 · Cited by 5
The administration of the opioid buprenorphine decreases motivational error signals
Pfabigan, D. M., Rütgen, M., Kroll, S. L., Riečanský, I., & Lamm, C. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105199 · Cited by 5
A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult
Blaszczyk, A. T., Mathys, M. L., & Le, J. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01051-3 · Cited by 9
Pain Management - From Acute to Chronic and Beyond
Aslanidis, T., & Nouris, C. (2023) · Pharmaceutical science. · doi:10.5772/intechopen.107760 · Cited by 5
The Diverse Clinical Uses of Opioid Receptor Drugs
Howland, R. H. (2010) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20100408-01 · Cited by 5
Magen, E., Geishin, A., & Lauden, A. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001311 · Cited by 5
Doleys, D. M. (2017) · Pain Physician · doi:10.36076/ppj/2017.7.e1095 · Cited by 6
Possible manic potential of buprenorphine
Jagadheesan, K., & Muirhead, D. (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1111/j.1440-1614.2004.01411.x · Cited by 5
A clinical snapshot of transdermal buprenorphine in pain management
Russo, M. A., & Wasiak, J. (2007) · European Journal of Pain Supplements · doi:10.1016/s1754-3207(08)60018-8 · Cited by 5
Li, Y., Niemelä, S., & Denissoff, A. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00642-x · Cited by 4
Adriaens, A., Polis, I., Vermeire, S. T., Waelbers, T., Croubels, S., Duchateau, L., Dorpe, S. V., Eersels, J. L. H., Spiegeleer, B. M. J. D., & Peremans, K. Y. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.004 · Cited by 4
Przewłocki, R., & Almeida, O. F. X. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803592-4.00008-0 · Cited by 4
Buprenorphine for the treatment of depression?
Balon, R. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12585 · Cited by 4
Endorphin Agonists for Severe Depression
Salerian, A. J. (2015) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2015.02.00017 · Cited by 3
Watt, D. F., & Panksepp, J. (2009) · Neuropsychoanalysis · doi:10.1080/15294145.2009.10773601 · Cited by 3
Canan, F. (2015) · Addiction & Addictive Disorders · doi:10.24966/aad-7276/100005 · Cited by 3
Goss, D. (2015) · Counselling Psychology Review · doi:10.53841/bpscpr.2015.30.1.52 · Cited by 3
Antidepressant in animal models of depression and study of cognitive property
Mankar, S. S., Turan, S. P., Mankar, S. S., & Shelke, P. A. (2019) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2019.7.3.0069 · Cited by 2
Opiophobia: Misinformation, Misconceptions, Misrepresentations, Perspectives, and Consequences
Bumpus, J. A. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00613 · Cited by 2
Pharmacotherapy of Dual Disorders
Soyka, M., & Grunze, H. (2014) · Springer eBooks · doi:10.1007/978-3-642-45375-5_19 · Cited by 2
Depressionen bei Abhängigkeitserkrankungen
Schäfer, M. K.-H., & Heinz, A. (2005) · Springer eBooks · doi:10.1007/3-540-28049-9_7 · Cited by 2
Major Depressive Disorder and Kappa Opioid Receptor
Li, W., Huijiao, S., Hao, C., Xicheng, Y., Li, X., Liu, R., Liming, S., & Zhui-bai, Q. (2016) · Translational Perioperative and Pain Medicine · doi:10.31480/2330-4871/035 · Cited by 2
The heroin epidemic (2000-2014): manmade influences
Salerian, A. J. (2018) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2018.06.00182 · Cited by 2
Sokhadze, E. M., Shaban, M., El-Baz, A. S., Tasman, A., Stewart, C., & Cannon, R. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89827-0.00022-x · Cited by 2
Fast Effect of Buprenorphine on Opioid-dependent Patients with Suicidal Ideation: A Novel Approach
Ahmadi, J., & Jahromi, M. S. (2018) · international journal high risk behaviors & addiction · doi:10.5812/ijhrba.57510 · Cited by 2
Acupuncture as a Modality for Treating Anxiety Related Disorders in Canines
Kontogianis, K. (2019) · Open Access Journal of Veterinary Science & Research · doi:10.23880/oajvsr-16000184 · Cited by 2
Substance Abuse and Depression
Lehmann, L. P. (2001) · CRC Press eBooks · doi:10.1201/b14027-4 · Cited by 2
Kaya-Akyüzlü, D., Özkan-Kotiloğlu, S., Şahiner, Ş. Y., ERTAN, E. A., & İlhan, İ. Ö. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174862 · Cited by 2
Possible Manic Potential of Buprenorphine
(2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01411.x · Cited by 2
Prescribing Opioids for Chronic Pain
Yoon, D., & Kang, U. (2019) · Journal of Korean Neuropsychiatric Association · doi:10.4306/jknpa.2019.58.3.182 · Cited by 2
Treatment-resistant depression amongst older adults: risk factors and treatment options.
Ebenezer, E. G. M. (2009) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp.9000285 · Cited by 1
Novel and Investigational Drugs in Depression
Shapiro, D. N., & Stahl, S. M. (2014) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2014/11590 · Cited by 1
Use of Adjunctive Therapy in Older Depressed Adults Who are Resistant to Antidepressant Treatment
Nelson, J. C. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796816.003.0021 · Cited by 1
Endorphin agonists for psychiatric disorders
Salerian, A. J. (2016) · Physical Medicine and Rehabilitation Research · doi:10.15761/pmrr.1000117 · Cited by 1
Metadata
- Authors
- Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O.
- Affiliations
- Harvard University (US)
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1995-02
- Volume
- 15
- Issue
- 1
- Pages
- 49-57
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2063621859
- Cited by
- 346
- References
- 39
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 9 · 2020: 19 · 2019: 22 · 2018: 25 · 2017: 18 · 2016: 20 · 2015: 20 · 2014: 21 · 2013: 18 · 2012: 13
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (DA-00115)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- buprenorphine, treatment-resistant depression, major depressive disorder, antidepressant treatment, opioid side effects
- MeSH terms
- Adult, Aged, Buprenorphine, Depressive Disorder, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
